- PharmaEssentia’s subsidiary FORUS Therapeutics received a Health Canada Notice of Compliance (NOC) for Besremi (ropeginterferon alfa-2b) to treat adults with polycythemia vera (PV).
- Besremi is a next-generation interferon shown to deliver durable hematologic and molecular responses, reduce symptom burden, and maintain a favorable safety profile in PV patients.
- The approval expands treatment options for polycythemia vera, a rare chronic blood cancer associated with an increased risk of thrombosis, stroke, myocardial infarction, myelofibrosis, and acute myeloid leukemia.
- Besremi is expected to become commercially available in Canada in the coming weeks, with PharmaEssentia working alongside Canadian hematologists to support patient access.
Takeaways:
The Canadian approval of Besremi gives PharmaEssentia a new, targeted therapy in the chronic myeloproliferative neoplasm space, expanding its hematology/oncology footprint beyond Taiwan and US markets. From a market perspective, it creates a differentiated, next-generation interferon option for polycythemia vera that can compete with older, less PV-specific interferons and oral agents, potentially improving disease control, symptom burden, and long-term outcomes for patients and their clinicians.
Source: Businesswire
